Precigen and recurrent respiratory papillomatosis foundation to hold inaugural international rrp awareness day on june 11th

–  inaugural multi-stakeholder event on june 11th (6/11)  will raise awareness and bring together individuals living with rrp, caregivers, clinicians, and government officials – –   rrp is a rare, hpv-driven disease with no fda-approved therapeutic – germantown, md. , march 28, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the company has teamed up with the recurrent respiratory papillomatosis foundation (rrpf) to launch the first rrp awareness day™ on june 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (rrp) and bring together rrp patients and their caregivers to encourage new connections and build community among those interested in and affected by this devastating disease.
PGEN Ratings Summary
PGEN Quant Ranking